{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:02:06Z","timestamp":1787065326395,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.canrad.2022.06.030","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T07:28:50Z","timestamp":1661239730000},"page":"979-986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Interactions of radiation therapy with common and innovative systemic treatments: Antidiabetic treatments, antihypertensives, lipid-lowering medications, immunosuppressive medications and other radiosensitizing methods"],"prefix":"10.1016","volume":"26","author":[{"given":"Y.","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Larnaudie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ghannam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ollivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Gounane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Laville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Coutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Huertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Maroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bockel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2022.06.030_bib0250","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaoncol.2021.2318","article-title":"Addition of metformin to concurrent chemoradiation in patients with locally advanced non-small cell lung cancer: the NRG-LU001 phase 2 randomized clinical trial","volume":"7","author":"Skinner","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0245","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamaoncol.2021.2328","article-title":"Metformin in combination with chemoradiotherapy in locally advanced non-small cell lung cancer: the OCOG-ALMERA randomized clinical trial","volume":"7","author":"Tsakiridis","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0280","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3727\/096504016X14719078133528","article-title":"A randomized controlled open-label pilot study of simvastatin addition to whole-brain radiation therapy in patients with brain metastases","volume":"24","author":"El-Hamamsy","year":"2016","journal-title":"Oncol Res"},{"key":"10.1016\/j.canrad.2022.06.030_bib0285","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s10637-020-00992-5","article-title":"Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study","volume":"39","author":"Altwairgi","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.canrad.2022.06.030_bib0290","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1186\/s12885-019-6405-7","article-title":"SPAR\u00a0\u2013\u00a0a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial","volume":"19","author":"Jameson","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2022.06.030_bib0300","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/COC.0000000000000289","article-title":"Utility of the ACE inhibitor captopril in mitigating radiation-associated pulmonary toxicity in lung cancer: results from NRG oncology RTOG 0123","volume":"41","author":"Small","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0305","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2018.10.035","article-title":"Daily lisinopril vs. placebo for prevention of chemoradiation-induced pulmonary distress in patients with lung cancer (alliance MC1221): a pilot double-blind randomized trial","volume":"103","author":"Sio","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2022.06.030_bib0320","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/ijc.30214","article-title":"Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study","volume":"139","author":"Pan","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canrad.2022.06.030_bib0325","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bulcan.2019.09.010","article-title":"[Radiotherapy and immune suppression: a short review]","volume":"107","author":"Bosacki","year":"2020","journal-title":"Bull Cancer"},{"key":"10.1016\/j.canrad.2022.06.030_bib0340","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/hed.20898","article-title":"Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck","volume":"31","author":"Shinohara","year":"2009","journal-title":"Head Neck"},{"key":"10.1016\/j.canrad.2022.06.030_bib0230","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.emboj.7600110","article-title":"LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK\/PAR-1","volume":"23","author":"Lizcano","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/j.canrad.2022.06.030_bib0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2020.06.030","article-title":"Metformin: (future) best friend of the radiation oncologist?","volume":"151","author":"Chevalier","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0240","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2012.12.004","article-title":"Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality","volume":"63","author":"Spratt","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0255","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13014-021-01935-x","article-title":"Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial","volume":"16","author":"Kim","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0260","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00464-017-5841-1","article-title":"Simvastatin enhances radiation sensitivity of colorectal cancer cells","volume":"32","author":"Karagkounis","year":"2018","journal-title":"Surg Endosc"},{"key":"10.1016\/j.canrad.2022.06.030_bib0265","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.urology.2006.08.1078","article-title":"Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer","volume":"68","author":"Tsai","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.canrad.2022.06.030_bib0270","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.ijrobp.2004.12.033","article-title":"Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer","volume":"62","author":"Katz","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2022.06.030_bib0275","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ijrobp.2009.12.006","article-title":"Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy","volume":"79","author":"Kollmeier","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2022.06.030_bib0295","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijrobp.2011.11.013","article-title":"Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy","volume":"84","author":"Kharofa","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2022.06.030_bib0310","first-page":"339","article-title":"Concomitant methotrexate and radiotherapy in advanced head and neck cancer: 15-year follow-up of a randomized clinical trial","volume":"13","author":"Gupta","year":"2001","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2022.06.030_bib0315","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0936-6555(05)80658-2","article-title":"An acute toxicity study on the effects of synchronous chemotherapy and radiotherapy in early stage breast cancer after conservative surgery","volume":"8","author":"Fernando","year":"1996","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2022.06.030_bib0330","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1097\/01.TP.0000137933.97259.E7","article-title":"Three-dimensional conformal radiotherapy for localized prostate cancer in kidney transplant recipients","volume":"78","author":"Mouzin","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.canrad.2022.06.030_bib0335","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.brachy.2013.11.003","article-title":"Locally advanced cervical cancer in renal transplant patients: a dilemma between control and toxicity","volume":"13","author":"Maroun","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.canrad.2022.06.030_bib0345","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","article-title":"Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)","volume":"22","author":"Wick","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2022.06.030_bib0350","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/neuonc\/noy161","article-title":"N2M2 (NOA-20) phase I\/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma","volume":"21","author":"Wick","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0355","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/neuonc\/nox209","article-title":"A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913","volume":"20","author":"Chinnaiyan","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0360","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/neuonc\/nou328","article-title":"A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K","volume":"17","author":"Ma","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0365","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2015.07.039","article-title":"A phase I-II study on the combination of rapamycin and short course radiotherapy in rectal cancer","volume":"116","author":"Buijsen","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0370","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2022.06.030_bib0375","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.radonc.2018.02.018","article-title":"DAHANCA 10\u00a0\u2013\u00a0effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group","volume":"127","author":"Overgaard","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0380","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","article-title":"Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia","volume":"25","author":"Wright","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0385","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/09553006914550741","article-title":"Electron-affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria","volume":"15","author":"Adams","year":"1969","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"key":"10.1016\/j.canrad.2022.06.030_bib0390","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13046-021-02000-x","article-title":"Interfering with tumor hypoxia for radiotherapy optimization","volume":"40","author":"Telarovic","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.canrad.2022.06.030_bib0395","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-8140(97)00220-X","article-title":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85","volume":"46","author":"Overgaard","year":"1998","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0400","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2020.07.037","article-title":"The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines","volume":"151","author":"Jensen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0405","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.2009.27.4449","article-title":"Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group","volume":"28","author":"Rischin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0410","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1200\/JCO.2005.01.3771","article-title":"Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003","volume":"23","author":"Williamson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0415","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1200\/JCO.2013.51.4265","article-title":"Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study","volume":"32","author":"DiSilvestro","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0420","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.ijrobp.2020.06.022","article-title":"Intratumoral hydrogen peroxide with radiation therapy in locally advanced breast cancer: results from a phase 1 clinical trial","volume":"108","author":"Nimalasena","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2022.06.030_bib0425","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/1078-0432.CCR-16-1297","article-title":"First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas","volume":"23","author":"Bonvalot","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2022.06.030_bib0430","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0435","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2021.01.007","article-title":"Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx","volume":"146","author":"Hoffmann","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2022.06.030_bib0440","first-page":"20180365","article-title":"AGuIX((R)) from bench to bedside-transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine","volume":"92","author":"Lux","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0445","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2021.04.021","article-title":"Theranostic AGuIX nanoparticles as radiosensitizer: a phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial)","volume":"160","author":"Verry","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2022.06.030_bib0450","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S1470-2045(20)30327-2","article-title":"Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study","volume":"21","author":"Sun","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321822001354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321822001354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:35:47Z","timestamp":1761136547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321822001354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":45,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1278321822001354"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2022.06.030","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions of radiation therapy with common and innovative systemic treatments: Antidiabetic treatments, antihypertensives, lipid-lowering medications, immunosuppressive medications and other radiosensitizing methods","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2022.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}